Strong growth in immunology and neurology prompted AbbVie to raise its 2026 outlook and consider future M&A from a position of “ample financial capacity.”

Original title: “AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate”

A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.

Original title: “Teva nabs experimental Tourette drug in $700M Emalex buyout”

Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market as patients end their 18-month course of Lilly’s product.

Original title: “Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla”

Partnership to support selection of first neoantigen therapy candidate

Original title: “Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy”

The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the cloud—a system that could “compress drug development timelines,” Jefferies analysts said.

Original title: “Amgen, AstraZeneca join FDA effort harnessing cloud for real-time clinical trials”

Angel investors are raising the bar with tighter criteria, backing strong teams, realistic markets and clear paths to exit while applying deeper, domain-specific diligence to early stage bets.

Original title: “Biotech angels lean into deeper diligence and disciplined early bets”

Altitude Labs, an offshoot of AI-focused techbio Recursion, is teaching scientists to build companies, one founder at a time.

Original title: “Altitude Labs serves up higher education for biotech founders”

With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.

Original title: “Lilly can’t stop the dealing, with nearly $21B spent on M&A this year—so far”

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.

Original title: “Pfizer deals extend patent life for a top-selling rare disease drug”